Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group.
2013
Aim: Around half of all women in Germany with breast cancer are older
than 65 and approximately one third of them is older than 70 years of age.
In theory, the preferred therapeutic management of women with breast cancer
aged 65 and above corresponds to that formulated for younger patients and
complies with the S3 Guidelines and the therapy recommendations formulated
by AGO. To study the current therapies used to treat women with breast
cancer aged 70 and above in Germany, a survey of the clinics of the German
Breast Group (GBG) was done. Method: An online survey was carried out
with requests sent to 599 physicians registered as principal investigators
in the database of the GBG. The 12-item questionnaire was used to
investigate the systematic therapeutic management of 70-year-old patients in
different settings. The indication for chemotherapy was taken as a given.
Results: In a neoadjuvant setting, 62 % of physicians opted for
anthracycline and taxane-based therapy as did 56.6 % of physicians in an
adjuvant setting. One third of physicians preferred a taxane-based therapy
with the anti-angiogenesis inhibitor bevacizumab as first-line therapy for
primary metastatic cancer and after anthracycline-based therapy.
Capecitabine (around 30 %) and navelbine (around 20 %) were proposed as
second-line neoadjuvant and adjuvant therapies after prior anthracycline-
and taxane-based therapy. Conclusion: The chemotherapy regimen
prescribed for women with breast cancer aged 70 and above in Germany appears
to be relatively standardised and corresponds to the recommendations given
in the S3 Guidelines and by the AGO Breast Committee.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
1
Citations
NaN
KQI